Identification

Name
Diethylpropion
Accession Number
DB00937  (APRD00919)
Type
Small Molecule
Groups
Approved, Illicit
Description

A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

Structure
Thumb
Synonyms
  • (+-)-Diethylpropion
  • (±)-diethylpropion
  • 1-phenyl-2-diethylamino-1-propanone
  • 2-(Diethylamino)-1-phenyl-1-propanone
  • 2-(Diethylamino)propiophenone
  • alpha-Benzoyltriethylamine
  • alpha-Diethylaminopropiophenone
  • Amfepramone
  • Amfepramonum
  • Anfepramona
  • Diethylcathinone
  • Diethylpropion
External IDs
DEA No. 1610
Product Ingredients
IngredientUNIICASInChI Key
Diethylpropion Hydrochloride19V2PL39NG134-80-5ICFXZZFWRWNZMA-UHFFFAOYNA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralNucare Pharmaceuticals, Inc.1960-11-17Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralActavis Pharma Company1960-11-17Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralA S Medication Solutions1960-11-172017-06-20Us
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralA S Medication Solutions1960-11-17Not applicableUs00591 0782 01 nlmimage10 fa45fd5f
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralPhysicians Total Care, Inc.2005-10-03Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralPreferreed Pharmaceuticals Inc.2014-02-12Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1Oralbryant ranch prepack2008-01-01Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralRebel Distributors2008-01-01Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralNucare Pharmaceuticals, Inc.1959-08-06Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralActavis Pharma Company1959-08-06Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralBlenheim Pharmacal, Inc.2010-03-30Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralCore Pharma, Llc2008-11-062016-03-16Us
Diethylpropion HydrochlorideTablet25 mg/1OralA S Medication Solutions2011-07-182017-06-20Us
Diethylpropion HydrochlorideTablet25 mg/1OralAidarex Pharmaceuticals LLC2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralLannett Company, Inc.2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralAidarex Pharmaceuticals LLC2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralUnit Dose Services2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralA S Medication Solutions2010-12-27Not applicableUs
International/Other Brands
Anorex / Dobesin / Frekentine / Linea / Moderatan / Neobes (Medix) / Nobesine / Prefamone / Regenon (Temmler) / Tepanil / Tylinal
Categories
UNII
Q94YYU22B8
CAS number
90-84-6
Weight
Average: 205.2961
Monoisotopic: 205.146664235
Chemical Formula
C13H19NO
InChI Key
XXEPPPIWZFICOJ-UHFFFAOYSA-N
InChI
InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
IUPAC Name
2-(diethylamino)-1-phenylpropan-1-one
SMILES
CCN(CC)C(C)C(=O)C1=CC=CC=C1

Pharmacology

Indication

Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

Structured Indications
Pharmacodynamics

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

Mechanism of action

Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent dopamine transporter
inhibitor
Human
Absorption

Diethylpropion is rapidly absorbed from the GI tract after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion.

Route of elimination

Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney.

Half life

Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.

Clearance
Not Available
Toxicity

The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Diethylpropion.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Diethylpropion.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Diethylpropion.Approved
AcrivastineDiethylpropion may decrease the sedative activities of Acrivastine.Approved
AlcaftadineDiethylpropion may decrease the sedative activities of Alcaftadine.Approved
AlfentanilDiethylpropion may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
AlimemazineDiethylpropion may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
AlphacetylmethadolDiethylpropion may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineDiethylpropion may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Diethylpropion.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Diethylpropion.Approved
Ammonium chlorideThe serum concentration of Diethylpropion can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Diethylpropion.Experimental
AntazolineDiethylpropion may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Diethylpropion.Approved
AstemizoleDiethylpropion may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of Diethylpropion.Vet Approved
AzatadineDiethylpropion may decrease the sedative activities of Azatadine.Approved
AzelastineDiethylpropion may decrease the sedative activities of Azelastine.Approved
BamipineDiethylpropion may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Diethylpropion.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Diethylpropion.Investigational
BezitramideDiethylpropion may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Diethylpropion.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Diethylpropion.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Diethylpropion.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Diethylpropion.Investigational
BrompheniramineDiethylpropion may decrease the sedative activities of Brompheniramine.Approved
BuclizineDiethylpropion may decrease the sedative activities of Buclizine.Approved
BuprenorphineDiethylpropion may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Diethylpropion.Experimental
ButorphanolDiethylpropion may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidDiethylpropion may decrease the sedative activities of Butyric Acid.Experimental
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
CarbinoxamineDiethylpropion may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilDiethylpropion may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Diethylpropion.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Diethylpropion.Withdrawn
CetirizineDiethylpropion may decrease the sedative activities of Cetirizine.Approved
ChloropyramineDiethylpropion may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineDiethylpropion may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineDiethylpropion may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Diethylpropion.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
CimetidineDiethylpropion may decrease the sedative activities of Cimetidine.Approved
CinnarizineDiethylpropion may decrease the sedative activities of Cinnarizine.Approved
ClemastineDiethylpropion may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of Diethylpropion.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Diethylpropion.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Diethylpropion.Experimental
ClozapineClozapine may decrease the stimulatory activities of Diethylpropion.Approved
CodeineDiethylpropion may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Diethylpropion.Approved
CyclizineDiethylpropion may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Diethylpropion.Approved
CyproheptadineDiethylpropion may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved
DesipramineDesipramine may increase the stimulatory activities of Diethylpropion.Approved
DesloratadineDiethylpropion may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineDiethylpropion may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineDiethylpropion may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleateDiethylpropion may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideDiethylpropion may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDiethylpropion may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineDiethylpropion may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may increase the stimulatory activities of Diethylpropion.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
DihydrocodeineDiethylpropion may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineDiethylpropion may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDiethylpropion may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDiethylpropion may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneDiethylpropion may decrease the sedative activities of Dimetindene.Approved
DimetotiazineDiethylpropion may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineDiethylpropion may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateDiethylpropion may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Diethylpropion.Experimental
DosulepinDosulepin may increase the stimulatory activities of Diethylpropion.Approved
DoxepinDiethylpropion may decrease the sedative activities of Doxepin.Approved
DoxylamineDiethylpropion may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEDiethylpropion may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
EbastineDiethylpropion may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Diethylpropion.Investigational
EmedastineDiethylpropion may decrease the sedative activities of Emedastine.Approved
EpinastineDiethylpropion may decrease the sedative activities of Epinastine.Approved, Investigational
EsmirtazapineDiethylpropion may decrease the sedative activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Diethylpropion.Approved
EthopropazineDiethylpropion may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Diethylpropion.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Withdrawn
EthylmorphineDiethylpropion may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtorphineDiethylpropion may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineDiethylpropion may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit, Withdrawn
FentanylDiethylpropion may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineDiethylpropion may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Diethylpropion.Experimental
FlunarizineDiethylpropion may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Diethylpropion.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Diethylpropion.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Diethylpropion.Approved, Vet Approved
Glutamic AcidThe serum concentration of Diethylpropion can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Diethylpropion can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Diethylpropion.Approved
HarmalineHarmaline may increase the hypertensive activities of Diethylpropion.Experimental
HeroinDiethylpropion may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of Diethylpropion.Experimental
HydrocodoneDiethylpropion may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneDiethylpropion may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
HydroxyzineDiethylpropion may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Diethylpropion.Approved
ImipramineImipramine may increase the stimulatory activities of Diethylpropion.Approved
Ioflupane I-123Diethylpropion may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Diethylpropion.Experimental
IproclozideIproclozide may increase the hypertensive activities of Diethylpropion.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Diethylpropion.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Diethylpropion.Approved
IsothipendylDiethylpropion may decrease the sedative activities of Isothipendyl.Approved
KetobemidoneDiethylpropion may increase the analgesic activities of Ketobemidone.Approved
KetotifenDiethylpropion may decrease the sedative activities of Ketotifen.Approved
LafutidineDiethylpropion may decrease the sedative activities of Lafutidine.Investigational
LavoltidineDiethylpropion may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineDiethylpropion may decrease the sedative activities of Levocabastine.Approved
LevocetirizineDiethylpropion may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateDiethylpropion may increase the analgesic activities of Levomethadyl Acetate.Approved
LevorphanolDiethylpropion may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of Diethylpropion.Approved
LodoxamideDiethylpropion may decrease the sedative activities of Lodoxamide.Approved
LofentanilDiethylpropion may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Diethylpropion.Experimental
LoratadineDiethylpropion may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Diethylpropion.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Diethylpropion.Approved
MagaldrateMagaldrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Diethylpropion.Withdrawn
MeclizineDiethylpropion may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Diethylpropion.Approved
MeptazinolDiethylpropion may increase the analgesic activities of Meptazinol.Experimental
MepyramineDiethylpropion may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineDiethylpropion may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Diethylpropion.Approved
MethadoneDiethylpropion may increase the analgesic activities of Methadone.Approved
Methadyl AcetateDiethylpropion may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneDiethylpropion may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MethenamineThe serum concentration of Diethylpropion can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Diethylpropion.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Diethylpropion.Investigational
MetiamideDiethylpropion may decrease the sedative activities of Metiamide.Experimental
MianserinDiethylpropion may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of Diethylpropion.Approved
MirtazapineDiethylpropion may decrease the sedative activities of Mirtazapine.Approved
MizolastineDiethylpropion may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Diethylpropion.Approved
MolindoneMolindone may decrease the stimulatory activities of Diethylpropion.Approved
MoperoneMoperone may decrease the stimulatory activities of Diethylpropion.Experimental
MorphineDiethylpropion may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Diethylpropion.Experimental
NalbuphineDiethylpropion may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Diethylpropion.Withdrawn
NicomorphineDiethylpropion may increase the analgesic activities of Nicomorphine.Experimental
NizatidineDiethylpropion may decrease the sedative activities of Nizatidine.Approved
NormethadoneDiethylpropion may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Diethylpropion.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Diethylpropion.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
OlopatadineDiethylpropion may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Diethylpropion.Approved
OpipramolOpipramol may increase the stimulatory activities of Diethylpropion.Investigational
OpiumDiethylpropion may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of Diethylpropion.Investigational
OxatomideDiethylpropion may decrease the sedative activities of Oxatomide.Investigational
OxycodoneDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneDiethylpropion may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Diethylpropion.Experimental
OzagrelDiethylpropion may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Diethylpropion.Approved
PargylinePargyline may increase the hypertensive activities of Diethylpropion.Approved
PemirolastDiethylpropion may decrease the sedative activities of Pemirolast.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of Diethylpropion.Experimental
PentazocineDiethylpropion may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Diethylpropion.Investigational
PerospironePerospirone may decrease the stimulatory activities of Diethylpropion.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Diethylpropion.Approved
PethidineDiethylpropion may increase the analgesic activities of Pethidine.Approved
PhenazocineDiethylpropion may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Diethylpropion.Approved
PhenindamineDiethylpropion may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Diethylpropion.Withdrawn
PheniramineDiethylpropion may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Diethylpropion.Approved
PhenoperidineDiethylpropion may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Diethylpropion.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Diethylpropion.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Diethylpropion.Approved
PipamperonePipamperone may decrease the stimulatory activities of Diethylpropion.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Diethylpropion.Approved
PiritramideDiethylpropion may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Diethylpropion.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Diethylpropion.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
PromethazineDiethylpropion may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Diethylpropion.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Diethylpropion.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Diethylpropion.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Diethylpropion.Approved
QuifenadineDiethylpropion may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of Diethylpropion.Investigational
RanitidineDiethylpropion may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Diethylpropion.Approved
RemifentanilDiethylpropion may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Diethylpropion.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Diethylpropion.Investigational
Roxatidine acetateDiethylpropion may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Diethylpropion.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
SufentanilDiethylpropion may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Diethylpropion.Approved
SultoprideSultopride may decrease the stimulatory activities of Diethylpropion.Experimental
TapentadolDiethylpropion may increase the analgesic activities of Tapentadol.Approved
TerfenadineDiethylpropion may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneDiethylpropion may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Diethylpropion.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of Diethylpropion.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Diethylpropion.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Diethylpropion.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Diethylpropion.Approved
ThonzylamineDiethylpropion may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Diethylpropion.Approved
TiaprideTiapride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
TilidineDiethylpropion may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Diethylpropion.Approved
TramadolDiethylpropion may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastDiethylpropion may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Diethylpropion.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Diethylpropion.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Diethylpropion.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Diethylpropion.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Diethylpropion.Approved
TripelennamineDiethylpropion may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineDiethylpropion may decrease the sedative activities of Triprolidine.Approved
TritoqualineDiethylpropion may decrease the sedative activities of Tritoqualine.Experimental
VeraliprideVeralipride may decrease the stimulatory activities of Diethylpropion.Experimental
Vitamin CThe serum concentration of Diethylpropion can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Diethylpropion.Approved
ZotepineZotepine may decrease the stimulatory activities of Diethylpropion.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).

US3001910
General References
  1. Adan RA, Vanderschuren LJ, la Fleur SE: Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. doi: 10.1016/j.tips.2008.01.008. Epub 2008 Mar 18. [PubMed:18353447]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
External Links
Human Metabolome Database
HMDB15072
KEGG Compound
C06954
PubChem Compound
7029
PubChem Substance
46506622
ChemSpider
6762
ChEBI
4530
ChEMBL
CHEMBL1194666
Therapeutic Targets Database
DAP001452
PharmGKB
PA164778098
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Diethylpropion
ATC Codes
A08AA03 — Amfepramone
AHFS Codes
  • 28:20.92
PDB Entries
Not Available
FDA label
Download (114 KB)
MSDS
Download (103 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentBMI >30 kg/m21

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Watson pharmaceuticals
  • 3m pharmaceuticals inc
  • Corepharma llc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Ucb inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral75 mg/1
TabletOral25 mg/1
Tablet, extended releaseOral75 mg/1
Capsule, extended releaseOral75 mg
TabletOral25 mg
Tablet, extended releaseOral75 mg
Prices
Unit descriptionCostUnit
Diethylpropion HCl CR 75 mg 24 Hour tablet1.0USD tablet
Tenuate 25 mg tablet0.67USD tablet
Diethylpropion 25 mg tablet0.52USD tablet
Diethylpropion HCl 25 mg tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP2.8ALOGPS
logP2.7ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)17.43ChemAxon
pKa (Strongest Basic)7.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity63.88 m3·mol-1ChemAxon
Polarizability24.12 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9354
Caco-2 permeable+0.8532
P-glycoprotein substrateNon-substrate0.5328
P-glycoprotein inhibitor INon-inhibitor0.8859
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.6691
CYP450 2C9 substrateNon-substrate0.8022
CYP450 2D6 substrateNon-substrate0.6551
CYP450 3A4 substrateNon-substrate0.6339
CYP450 1A2 substrateInhibitor0.7358
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.7815
CYP450 2C19 inhibitorNon-inhibitor0.8088
CYP450 3A4 inhibitorNon-inhibitor0.9438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6602
Ames testNon AMES toxic0.9326
CarcinogenicityCarcinogens 0.5877
BiodegradationNot ready biodegradable0.9236
Rat acute toxicity2.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8475
hERG inhibition (predictor II)Non-inhibitor0.8179
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-9600000000-6ee5a640521355e9e385
Mass Spectrum (Electron Ionization)MSsplash10-0udi-2900000000-43214c102b76f59ba4d1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Alpha-amino ketones / Trialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Phenylpropane / Benzoyl / Aryl alkyl ketone / Benzenoid / Monocyclic benzene moiety / Alpha-aminoketone / Tertiary aliphatic amine / Tertiary amine / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amine, aromatic ketone (CHEBI:4530)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC: Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem. 2000 Dec;8(12):2689-92. [PubMed:11131159]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:48